Monoclonal antibody lowers migraine days in adults with prior preventive treatment failure

In adults with prior preventive migraine treatment failures, an investigational monoclonal antibody led to larger decreases in monthly migraine days vs. placebo, according to a poster presented at a recent conference.Bocunebart (Lu AG09222, Lundbeck) is a monoclonal antibody that targets the pituitary adenylate cyclase-activating polypeptide (PACAP) ligand, according to the presentation at the

Raccontata dahealio.com